JNMT
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McGough, C. G.
Right arrow Articles by Hung, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGough, C. G.
Right arrow Articles by Hung, J. C.

Journal of Nuclear Medicine Technology, Vol 27, Issue 3 227-229, Copyright © 1999 by Society of Nuclear Medicine

ARTICLES

Comparison of four 1-mL syringes for administering first-pass radionuclide angiography doses

CG McGough, DC Huang and JC Hung
Nuclear Medicine, Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA.

OBJECTIVE: For optimal imaging in first-pass radionuclide angiography (FPRNA) studies, 1.11 GBq (30 mCi) 99mTc-sestamibi doses are drawn up in volumes of 0.1-0.3 mL. A single bolus injection of this small volume is important to obtain accurate time-activity curves. Because of the small volume and concentrated radioactivity, it is undesirable for study effectiveness and image quality to have a significant amount of residual activity remaining in the syringe after injection. The purpose of this study was to compare the amount of residual activity in 4 different 1-mL syringes. METHODS: Each test syringe (n = 20) was filled with a volume (0.2 mL) of approximately 1.11 GBq (approximately 30 mCi) 99mTc-sestamibi. Initial activity was measured, and the dose was injected back into a vial only once, simulating bolus injection into a patient. The remaining activity was measured, followed by the calculation of percent residual activity. RESULTS: The two 25-G x 5/8-in. permanent needles had a low percent of residual activity, as well as a much sturdier needle for injection. However, one of these syringes is more expensive. CONCLUSION: The results of our comparison studies showed that the syringe with a 25-G x 5/8-in. permanent needle is ideal for FPRNA doses because of its sturdiness, low residual activity, and the quality of the bolus and resulting images.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE JOURNAL OF NUCLEAR MEDICINE JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
Copyright © 1999 by the Society of Nuclear Medicine Technologist Section.